
OMDA Stock Forecast & Price Target
OMDA Analyst Ratings
Bulls say
Omada Health Inc. has demonstrated robust financial growth, achieving a total revenue increase of 49.5% year-over-year, driven by a surge in platform membership, which reached 831,000 by the end of Q3 2025—substantially exceeding initial estimates. The company has successfully expanded its GLP-1 program, adding approximately 100,000 members in 2025 and achieving over 50% revenue growth linked to this initiative, highlighting strong demand for its integrated health solutions. Furthermore, predictions of significant growth in the obesity drug market, projected to soar to $60 billion by 2029, align well with Omada's strategic focus on chronic condition management, enhancing its long-term growth prospects.
Bears say
Omada Health Inc has exhibited concerning trends in its financial metrics, particularly with a decrease in adjusted R&D as a percentage of services revenue from 28% in 2023 to 16% in 2025, indicating potential underinvestment in innovation relative to revenue growth. Additionally, the company's current trading multiples of 28x and 21x EBITDA estimates for 2027 and 2028, paired with a projected CAGR of only 54% from 2026 to 2028, suggest investor skepticism about its long-term growth trajectory compared to historical peaks and market expectations. Furthermore, the potential shift of health plans towards internalized care management programs could further constrict Omada's growth prospects, compounded by the introduction of lower-cost oral therapies that may challenge the ongoing demand for its GLP-1 initiatives.
This aggregate rating is based on analysts' research of Omada Health Inc and is not a guaranteed prediction by Public.com or investment advice.
OMDA Analyst Forecast & Price Prediction
Start investing in OMDA
Order type
Buy in
Order amount
Est. shares
0 shares